Literature DB >> 24687415

Saudi Atrial Fibrillation Survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation.

Ahmad Hersi1, Mohammad Abdul-Moneim2, Abdulmohsen Almous'ad3, Faisal Al-Samadi4, Ahmed AlFagih5, Raid Sweidan6.   

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The Saudi Atrial Fibrillation Survey registry was designed to provide epidemiological and clinical data on patients with AF. The registry included 400 consecutive patients who met the eligibility criteria. Control of AF at the time of the initial visit was achieved by 211 (52.75%) patients. Cardiovascular risk profile of the patients with AF was smoking 92 (23.5%), hypertension 253 (63.25%), diabetes 192 (48%), and dyslipidemia 173 (44%). Rate control was the most frequent management strategy (in 265 patients, 66.2%) whereas rhythm control was chosen in 48 (12%) patients. Both strategies were attempted in 5 (1.2%) patients. This is the first nationwide registry of patients with AF in Saudi Arabia. Compared to developed countries, our patients with AF are relatively young and have higher rates of diabetes and rheumatic heart disease. Rate control is the main strategy currently used for managing AF.
© The Author(s) 2014.

Entities:  

Keywords:  Saudi Arabia; atrial fibrillation; survey

Mesh:

Substances:

Year:  2014        PMID: 24687415     DOI: 10.1177/0003319714529180

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

2.  Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia.

Authors:  Abdulrahman M Al-Turaiki; Maha A Al-Ammari; Shmeylan A Al-Harbi; Nabil S Khalidi; Abdulmalik M Alkatheri; Tariq M Aldebasi; Salah M AbuRuz; Abdulkareem M Albekairy
Journal:  Ann Thorac Med       Date:  2016 Apr-Jun       Impact factor: 2.219

Review 3.  Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa.

Authors:  Ahmad S Hersi; Yahya S Alhebaishi; Omar Hamoui; Taher Hassan; Adel Khalifa Hamad; Mohamed Magdy; Hani Sabbour; Sameh Shaheen
Journal:  J Saudi Heart Assoc       Date:  2017-06-08

4.  Risk of postoperative bleeding following dental extractions in patients on antithrombotic treatment.

Authors:  Mohammed AlSheef; Jenny Gray; AbdulSalam AlShammari
Journal:  Saudi Dent J       Date:  2020-09-24

5.  One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.

Authors:  Ayman Hammoudeh; Yousef Khader; Ramzi Tabbalat; Yahya Badaineh; Nazih Kadri; Haneen Shawer; Eyas Al-Mousa; Rasheed Ibdah; Batool A Shawer; Imad A Alhaddad
Journal:  Int J Vasc Med       Date:  2022-04-13

Review 6.  Barriers to stroke prevention in Atrial Fibrillation: Insights from the global anticoagulation Roundtable.

Authors:  Geoffrey D Barnes; Gregory Piazza
Journal:  Int J Cardiol Heart Vasc       Date:  2022-08-01

7.  Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia.

Authors:  Abdullah Abdulfattah Mashat; Ahmed Hussein Subki; Moaz Abdulrahman Bakhaider; Wejdan Mohammad Baabdullah; Jawaher Badr Walid; Abdulrahman Hatim Alobudi; Maged Mazen Fakeeh; Anas Jamal Algethmi; Wesam Awad Alhejily
Journal:  Int J Gen Med       Date:  2019-01-11

8.  Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.

Authors:  Ahmad S Hersi; Katherine M Osenenko; Sid Ahmed Kherraf; Ayman Abdel Aziz; Robert Joseph Sambrook
Journal:  Ann Saudi Med       Date:  2019-08-05       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.